Zobrazeno 1 - 3
of 3
pro vyhledávání: '"James M. Orcutt"'
Autor:
Samuel A. Jacobs, André Robidoux, Jame Abraham, José Manuel Pérez-Garcia, Nicla La Verde, James M. Orcutt, Marina E. Cazzaniga, Fanny Piette, Silvia Antolín, Elena Aguirre, Javier Cortes, Antonio Llombart-Cussac, Serena Di Cosimo, Rim S. Kim, Huichen Feng, Corey Lipchik, Peter C. Lucas, Ashok Srinivasan, Ying Wang, Nan Song, Patrick G. Gavin, April D. Balousek, Soonmyung Paik, Carmen J. Allegra, Norman Wolmark, Katherine L. Pogue-Geile
Publikováno v:
Breast Cancer Research, Vol 21, Iss 1, Pp 1-11 (2019)
Abstract Purpose The primary aim of NSABP FB-7 was to determine the pathologic complete response (pCR) rate in locally advanced HER2-positive (HER2+) breast cancer patients treated with neoadjuvant trastuzumab or neratinib or the combination and week
Externí odkaz:
https://doaj.org/article/8c6fc04f4e924176a82cabe4e3ccf226
Autor:
Samuel A. Jacobs, André Robidoux, Jame Abraham, José Manuel Pérez-Garcia, Nicla La Verde, James M. Orcutt, Marina E. Cazzaniga, Fanny Piette, Silvia Antolín, Elena Aguirre, Javier Cortes, Antonio Llombart-Cussac, Serena Di Cosimo, Rim S. Kim, Huichen Feng, Corey Lipchik, Peter C. Lucas, Ashok Srinivasan, Ying Wang, Nan Song, Patrick G. Gavin, April D. Balousek, Soonmyung Paik, Carmen J. Allegra, Norman Wolmark, Katherine L. Pogue-Geile
Publikováno v:
Breast Cancer Research, Vol 22, Iss 1, Pp 1-2 (2020)
After the publication of this work [1] the authors have reported that in Table 3 The letter “T” in columns 5 and 7 should not be there.
Externí odkaz:
https://doaj.org/article/1224ca9686ff4ace8904fdb0d7ec7ea5
Autor:
Jose Perez-Garcia, Peter C. Lucas, Rim S. Kim, Nan Song, Antonio Llombart-Cussac, Nicla La Verde, Soonmyung Paik, Javier Cortes, Silvia Antolín, Marina Elena Cazzaniga, Ying Wang, James M. Orcutt, Elena Aguirre, Fanny Piette, Samuel A. Jacobs, Huichen Feng, Carmen J. Allegra, Katherine L. Pogue-Geile, Patrick G. Gavin, Jame Abraham, Corey Lipchik, Serena Di Cosimo, André Robidoux, Ashok Srinivasan, Norman Wolmark, April D. Balousek
Publikováno v:
Breast Cancer Research, Vol 22, Iss 1, Pp 1-2 (2020)
The primary aim of NSABP FB-7 was to determine the pathologic complete response (pCR) rate in locally advanced HER2-positive (HER2+) breast cancer patients treated with neoadjuvant trastuzumab or neratinib or the combination and weekly paclitaxel fol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86fc10ddf2ec025789e4fd26b29bfc24
http://hdl.handle.net/10281/259971
http://hdl.handle.net/10281/259971
